## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.5% in lower entry zone (4.0-10.0%), top 4% cross-sectional ranking. Short-term MRS_5 (0.8%) confirms momentum alignment. Outperforming sector by 6.3%. Caution: momentum weakening (-2.5% MRS), overbought RSI (77).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($11.64)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 3, Bearish: 3)

**1. Viatris Inc. stock rises Wednesday, outperforms market**
- Source: MarketWatch | 20251224T163000 | Bullish | Relevance: 100%
- Viatris Inc. (VTRS) stock increased by 1.83% to $12.24 on Wednesday, outperforming the broader market. This marked the stock's third consecutive day of gains, as the S&P 500 Index and Dow Jones Industrial Average also saw increases.

**2. Viatris Inc. stock rises Wednesday, outperforms market**
- Source: MSN | 20251224T221254 | Somewhat-Bullish | Relevance: 100%
- Viatris Inc. (VTRS) stock saw a gain of 2.15% on Wednesday, closing at $11.85, which outperformed the broader market's daily decline. Despite this daily gain, the stock remains below both its 52-week high and its 50-day moving average.

**3. Prescription for Growth: Why Zoetis and Viatris are Defining Healthcareâ€™s New Winners in 2025**
- Source: FinancialContent | 20251224T173000 | Bullish | Relevance: 100%
- In 2025, while the broader healthcare sector faced challenges, Zoetis Inc. (NYSE: ZTS) and Viatris Inc. (NASDAQ: VTRS) emerged as leaders due to their specialized focus on animal health and specialty/complex generics, respectively. Both companies demonstrated strong performance, with Viatris achieving a "beat and raise" quarter and Zoetis navigating regulatory scrutiny by highlighting its innovative pipeline in pet care. Their success underscores a shift towards specialized portfolios that are more resilient to policy changes and broader market volatility.

**4. DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris**
- Source: KTLA | 20251224T170906 | Bearish | Relevance: 100%
- Faruqi & Faruqi, LLP is investigating potential securities claims against Viatris, Inc. (NASDAQ: VTRS) following a significant stock price drop. The investigation focuses on allegations that Viatris made misleading statements about its revenue outlook and minimized the impact of a failed FDA inspection at its Indore facility. Investors who suffered losses exceeding $100,000 are encouraged to contact the firm by the June 3, 2025, lead plaintiff deadline.

**5. Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Recover Losses - Contact Levi & Korsinsky Before June 3, 2025**
- Source: KGET.com | 20251224T160843 | Bearish | Relevance: 100%
- Levi & Korsinsky LLP has filed a class action securities lawsuit against Viatris Inc. (NASDAQ:VTRS) on behalf of shareholders who experienced losses between August 8, 2024, and February 26, 2025. The lawsuit alleges that Viatris misrepresented the impact of an FDA warning letter concerning its Indore, India facility, leading to a significant stock price decline after disappointing 2025 guidance was announced. Investors are encouraged to contact the firm by June 3, 2025, to learn about their rights to recover losses.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 5.0x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.1B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.68 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 5.0 |
| Current P/E | 5.3 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 9.0% to 6.5% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 96th percentile. MRS_5 at 0.8% confirms short-term momentum alignment. AM_20 at 7.7% shows strong absolute momentum above own 20MA. Outperforming sector by 6.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 77, risk of mean reversion. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.49% (CS: 96) | Strong |
| RSI_14 | 77.0 | Overbought |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.077x | Above |
| vs SMA50 | 1.132x | Above |
| vs SMA200 | 1.278x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $12.24
- **Stop Loss:** $11.64 (4.9% risk)
- **Target:** $13.14 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2000
- **Position Value:** $24,480.00
- **Portfolio %:** 24.48%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*